754 Phase 1 trial of LYL797, a ROR1-targeted CAR T-cell therapy enhanced with genetic and epigenetic reprogramming, in advanced triple-negative breast cancer (TNBC) and non-small cell lung cancer (NSCLC)

David R. Spigel, Heidi H. Gillenwater, Hemant S. Murthy et al.|Regular and Young Investigator Award Abstracts|2023

Cited by 4